The "Alpha-Emitter" Ascension: Is 2026 the Year Actinium-225 Goes Mainstream?
A major shift in the 2026 global industry is the record-breaking transition to Targeted Alpha Therapy (TAT). This year, following the landmark "Actinium-225 Supply Agreements" of late 2025, the market is seeing the first wave of clinical results for 225Ac-PSMA. Unlike beta-emitters, alpha particles act like "biological wrecking balls," traveling only a few cell-widths but delivering enough...
0 Reacties
0 aandelen
730 Views
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt